Protective activity of a murine monoclonal antibody against acute and chronic experimental infection with type IV group B streptococcus

References

1. Baker C. J., Edwards M. S. Group B streptococcal infections. In Remington J. S., Klein J. O. (eds) Infectious diseases of the fetus and newborn infant Philadelphia: WB Saunders Company; 1983820–881
   [Google Scholar]
2. Eykyn S. J., Young S. E. J., Cookson B. D. Increased community-acquired septicaemic infection with group B streptococci in adults. Lancet 1991; 338:446
   [Google Scholar]
3. Farley M. M., Harvey R. C., Stull T. A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. N Engl J Med 1993; 328:1807–1811
   [Google Scholar]
4. Rubens C. E., Wessels M. R., Heggen L. M., Kasper D. L. Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence. Proc Natl Acad Sci USA 1987; 84:7208–7212
   [Google Scholar]
5. Baker C. J., Kasper D. L. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 1976; 294:753–756
   [Google Scholar]
6. Fischer G. W., Weisman L. E., Hemming V. G. Directed immune globulin for the prevention or treatment of neonatal group B streptococcal infections: a review. Clin Immunol Immunopathol 1992; 62:S92–S97
   [Google Scholar]
7. Fischer G. W., Weisman L. B., Hemming V. G. Intravenous immunoglobulin in neonatal group B streptococcal disease. Pharmacokinetic and safety studies in monkeys and humans. Am J Med 1984; 76:S117–S123
   [Google Scholar]
8. Kim K. S., Wass C. A., Kang J. H., Anthony B. F. Functional activities of various preparations of human intravenous immunoglobulin against type III group B Streptococcus. J Infect Dis 1986; 153:1092–1097
   [Google Scholar]
9. Weisman L. E., Anthony B. F., Hemming V. G., Fischer G. W. Comparison of group B streptococcal hyperimmune globulin and standard intravenously administered immune globulin in neonates. J Pediatr 1993; 122:929–937
   [Google Scholar]
10. Egan M. L., Pritchard D. G., Dillon H. C., Gray B. M. Protection of mice from experimental infection with type III group B Streptococcus using monoclonal antibodies. J Exp Med 1983; 158:1006–1011
    [Google Scholar]
11. Shigeoka A. O., Pincus S. H., Rote N. S., Hill H. R. Protective efficacy of hybridoma type-specific antibody against experimental infection with group-B Streptococcus. J Infect Dis 1984; 149:363–372
    [Google Scholar]
12. Gray B. M., Egan M. L., Pritchard D. G. Specificity of monoclonal antibodies against group B Streptococcus type II and inhibition of their binding by human secretions. Pediatr Res 1988; 24:68–72
    [Google Scholar]
13. Raff H. V., Siscoe P. J., Wolff E. A., Maloney G., Shuford W. Human monoclonal antibodies to group B Streptococcus. Reactivity and in vivo protection against multiple serotypes. J Exp Med 1988; 168:905–917
    [Google Scholar]
14. Teti G., Calapai M., Calogero G. Specificity and protective activity of murine monoclonal antibodies directed against the capsular polysaccharide of type III group B streptococci. Hybridoma 1992; 11:13–22
    [Google Scholar]
15. Hill H. R., Kelsey D. K., Gonzales L. A., Raff H. V. Monoclonal antibodies in the therapy of experimental neonatal group B streptococcal disease. Clin Immunol Immunopathol 1992; 62:S87–S91
    [Google Scholar]
16. Tissi L., Marconi P., Mosci P. Experimental model of type IV Streptococcus agalactiae (Group B Streptococcus) infection in mice with early development of septic arthritis. Infect Immun 1990; 58:3093–3100
    [Google Scholar]
17. Rabinowitz S., Feme M., Halfon S. T. Group B streptococci: different serotypes associated with clinical infection. Lab Pract 1980; 29:733–734
    [Google Scholar]
18. Jelinkova J., Motlova J. Worldwide distribution of two new serotypes of group B streptococci: type IV and provisional type V. J Clin Microbiol 1985; 21:361–362
    [Google Scholar]
19. Wessels M. R., Benedi V. J., Jennings H. J., Michon F., DiFabio J. L., Kasper D. L. Isolation and characterization of type IV group B Streptococcus capsular polysaccharide. Infect Immun 1989; 57:1089–1094
    [Google Scholar]
20. Molinari A., von Hunolstein C., Donelli G., Paradisi S., Aranda G., Orefici G. Effects of some capsular components on pathogenicity of type IV and provisional type V group B streptococci. FEMS Microbiol Lett 1987; 41:69–72
    [Google Scholar]
21. von Hunolstein C., D’ascenzi S., Wagner B. Immuno-chemistry of capsular type polysaccharide and virulence properties of type VI Streptococcus agalactiae (Group B streptococci). Infect Immun 1993; 61:1272–1280
    [Google Scholar]
22. Lancefield R. C. A serological differentiation of specific types of bovine hemolytic streptococci (group B). J Exp Med 1934; 59:441–458
    [Google Scholar]
23. Malavasi F., Caligaris-Cappio F., Milanese C., Dellabona P., Richiardi P., Carbonara A. O. Characterization of a murine monoclonal antibody specific for human early lymphohema-poietic cells. Human Immunol 1984; 9:9–20
    [Google Scholar]
24. Ouchterlony O. Diffusion-in-gel methods for immunological analysis. Prog Allergy 1958; 5:1–78
    [Google Scholar]
25. Reed L., Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938; 27:493–397
    [Google Scholar]
26. Lancefield R. C., McCarty M., Everly W. N. Multiple mouse-protective antibodies directed against group B streptococci. J Exp Med 1975; 142:165–179
    [Google Scholar]
27. Shigeoka A. O., Hall R. T., Hill H. R. Blood-transfusion in group-B streptococcal sepsis. Lancet 1978; 1:636–638
    [Google Scholar]
28. Butkus Small C., Slater L. N., Lowry F. D., Small R. D., Salvati E. A., Casey J. L. Group B streptococcal arthritis in adults. Am J Med 1984; 76:367–375
    [Google Scholar]
29. Raff H. Y., Bradley C., Brady W. Comparison of functional activities between IgGl and IgM class-switched human monoclonal antibodies reactive with group B streptococci or Escherichia coli Kl. J Infect Dis 1991; 163:346–354
    [Google Scholar]